Our pharmaceuticals business provides a wide range of pharmaceuticals and diagnostic reagents. As a specialized, R&D-centered operation, the development of new world-class drugs is advanced to offer innovative and unique therapeutic solutions in the fields of orthopedics, critical/intensive care, urology, the immune system, and the central nervous system.
Since the development of Japan’s first original antibiotic in 1954, we have advanced the development of many innovative new drugs centering on the fields of orthopedics, the circulatory system, urology, the immune system, and the central nervous system. Our pharmaceutical product lineup includes drugs for osteoporosis, a rheumatoid arthritis agent, a therapy for Dupuytren’s contracture, an anticoagulant, an agent for benign prostatic hyperplasia, an immunosuppressant, an antidepressant, and a Rho-kinase inhibitor. Each is competitive in its respective market.
Our diagnostic reagents and assay kits utilize enzyme technology to support health maintenance. These include an assay kit used to measure glycated albumin, newly recognized as an effective indicator for the management of diabetes; an assay kit used to measure myoinositol concentration in urinary samples as a simple and effective screening test for diabetes; and a diagnostic test kit launched in 2013 to aid the rapid diagnosis of mycoplasma infection.